• Log In or Create Account
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
Advanced Search
The Future of ART - IAS-USA
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs

The Future of ART

The Future of ART

The Future of ART
Presenter: Roy M. Gulick, MD, MPH

Slides

On-Demand Webcast

Podcast

iasusa · The Future of ART

The Future of ART - IAS-USA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

  • Home
  • Activities
  • Resources
  • About
  • Contact
  • Login
  • Careers
  • Donate
  • Website Policies
© 2026 International Antiviral Society–USA. All Rights Reserved.
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs
Practice Question of the Week

October 12, 2026: Simplifying Antiretroviral Regimens in Virologically Suppressed Patients With Drug Resistance

You are caring for a patient who has a history of virologic failure with known nucleoside reverse transcriptase inhibitor (nRTI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance. He has most recently been on darunavir (DRV)/cobicistat (cobi)/tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG) with good tolerance, adherence, and viral suppression. Although this regimen is only 2 pills per day, he is very interested in something even simpler and with smaller pills. You discuss a variety of options, including bictegravir (BIC)/lenacapavir (LEN). Which of the following statements regarding the ARTISTRY-1 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen) trial is TRUE?
Register for the Chicago Course
View Archived Questions
Leave Feedback
Subscribe